Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

Incyte (INCY) “announced that the FDA has approved Opzelura cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous ...

The U.S. Food and Drug Administration has approved Incyte's eczema treatment for children aged between 2 and 11 years, the ...

Nektar Therapeutics (NASDAQ:NKTR) stock rose 7% Thursday following the announcement of encouraging outcomes from its REZOLVE-AD Phase 2b study of rezpegaldesleukin for patients with moderate-to-severe ...

A new international study presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals ...

Adults with atopic dermatitis, whether diagnosed during childhood or adulthood, experienced higher rates of suicidal thoughts ...

Nektar Therapeutics (Nasdaq: NKTR) today announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, ...